APTOSE     Print Page | Close Window

2017 Press Releases

Keyword Search
 
2017 | 2016 | 2015 | 2014 | 2013
September 19, 2017
Aptose to Present at the 17th Annual Biotech in Europe Forum
September 12, 2017
Aptose Biosicences and CrystalGenomics Announce Issuance of U.S. Patent for CG’806
September 5, 2017
Aptose Biosciences to Present at the 19th Annual Rodman & Renshaw Global Investment Conference
August 8, 2017
Aptose Reports Results for the Second Quarter Ended June 30, 2017
August 3, 2017
Aptose Biosciences to Present at Canaccord Genuity 37th Annual Growth Conference
August 1, 2017
Aptose To Release Second Quarter Ended June 30, 2017 Financial Results and Hold Conference Call on August 8, 2017
June 6, 2017
Aptose Biosciences Announces Results of Annual Meeting of Shareholders
May 11, 2017
Aptose Reports Results for the First Quarter Ended March 31, 2017
May 8, 2017
Preclinical Data on Aptose Biosciences FLT3/BTK Inhibitor CG’806 Presented at AACR Hematologic Malignancies Meeting
May 8, 2017
OHSU and Aptose Present CG’806 Preclinical Data Demonstrating Potent Activity Against Patient Samples at AACR Hematologic Malignancies Meeting
April 25, 2017
Aptose Biosciences to Participate at the Bloom Burton & Co. Healthcare Investor Conference 2017
April 24, 2017
Aptose To Release First Quarter Ended March 31, 2017 Financial Results and Hold Conference Call on May 11, 2017
April 19, 2017
Aptose Biosciences to Present CG’806 Data at AACR Hematologic Malignancies Meeting
March 28, 2017
Aptose Reports Fourth Quarter and Year End 2016 Results
March 28, 2017
Aptose Reports Fourth Quarter and Year End 2016 Results
March 27, 2017
Aptose Announces Planned Departure of Chief Business Officer
March 2, 2017
Aptose to Participate in Upcoming Investor Conferences
February 2, 2017
Aptose Biosciences to Present at Canaccord Genuity Rare Disease Biopharma 1x1 Day
January 23, 2017
Aptose Prioritizes Development of CG’806 First-in Class FLT3/BTK Inhibitor
January 5, 2017
Aptose Biosciences to Present at Biotech Showcase 2017 Conference